Compare Ishares Msci Thailand Etf (THD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Thailand Etf vs Vertex Pharmaceuticals Incorporated — how do they compare? Ishares Msci Thailand Etf trades at $75.04, while Vertex Pharmaceuticals Incorporated trades at $528 (market cap $138.42B). The key difference: Ishares Msci Thailand Etf is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| THD | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $75.06 | $557.96 |
52-Week Low | $57.86 | $376.62 |
Market Cap | — | $138.42B |
Enterprise Value | — | $132.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
THD trades at $75.06, up 2.28% with a $1.67 gain, showing recent positive momentum despite an overall bearish technical signal. The stock faces headwinds with moving averages indicating selling pressure while oscillators remain neutral. Recent news highlights THD's exposure to AI hardware through Delta Electronics, driving strong 38% annual returns but creating vulnerability to sector rotation. The upcoming dividend of $1.71 scheduled for June 2026 provides income appeal.
Outlook remains cautious as technical indicators suggest continued bearish pressure near-term, though oversold conditions could present entry opportunities. Key risks include dependence on AI sector performance and foreign capital flows. Investors should monitor Thailand's economic policies and global semiconductor trends for directional cues on this ASEAN-focused ETF.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $548.78. The company reported strong 2025 results with $12.0B revenue and $3.95B net income, though recent quarterly EPS results were mixed. Key developments include the acquisition of Crinetics Pharmaceuticals, completed September 1, 2026, expanding its therapeutic pipeline.
The outlook remains positive given robust profitability margins, institutional accumulation, and limited competition in core markets. Risks include integration challenges from acquisitions and clinical trial setbacks. Wall Street sentiment is overwhelmingly bullish, with 86% of analysts rating the stock a buy, supporting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
